Status:

NOT_YET_RECRUITING

12-Month Efficacy of Exercise and Cytisinicline for Tobacco Abstinence

Lead Sponsor:

Maimónides Biomedical Research Institute of Córdoba

Collaborating Sponsors:

Universidad de Córdoba

Conditions:

Smoking Cessation

Eligibility:

All Genders

18-65 years

Phase:

PHASE4

Brief Summary

Current scientific evidence demonstrates the relationship between good physical fitness and a lower incidence of certain chronic diseases, including smoking, as well as the effectiveness of cytisinicl...

Eligibility Criteria

Inclusion

  • Aged between 18 and 65 years.
  • Smoking a minimum of 10 cigarettes per day.
  • In the contemplation or action stage according to Prochaska and DiClemente's Transtheoretical Model.
  • Prepared to initiate smoking cessation treatment imminently and with commitment.
  • Demonstrating a high level of nicotine dependence, with a Fagerström test score of 7 or higher.
  • Exhibiting significant motivation to quit smoking, as indicated by a Richmond test score of 6 or higher.
  • Having made at least one prior attempt to quit smoking within the past year.
  • Enrolled in or covered by the Andalusian Public Health System.

Exclusion

  • Individuals with medical conditions that contraindicate participation in physical exercise, including but not limited to malignant hypertension, heart failure, hyperthyroidism, peripheral arterial disease, or other conditions deemed by the research team to pose a risk of adverse events or significantly impair adherence to the study.
  • Individuals who have experienced changes in their usual treatment regimen within the past 90 days.
  • Individuals unable to provide informed consent.
  • Individuals with pathological conditions that significantly reduce life expectancy to less than 5 years.
  • Individuals with contraindications as specified in the product information for cytisinicline , such as pregnancy, breastfeeding, hypersensitivity to cytisinicline, unstable angina, recent myocardial infarction, clinically significant arrhythmias, or recent stroke.

Key Trial Info

Start Date :

January 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2025

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT06579846

Start Date

January 1 2025

End Date

December 31 2025

Last Update

September 4 2024

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

12-Month Efficacy of Exercise and Cytisinicline for Tobacco Abstinence | DecenTrialz